A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

September 18, 2023

Study Completion Date

October 16, 2023

Conditions
Major Depressive Disorder
Interventions
DRUG

XEN1101 10 mg

XEN1101 oral capsule

DRUG

XEN1101 20 mg

XEN1101 oral capsule

DRUG

Placebo

Placebo capsule

Trial Locations (20)

10036

Manhattan Behavioral Medicine, PLLC, New York

11516

Neurobehavioral Research, Inc. (NBR), Cedarhurst

27609

Richard M Weisler and Association, Raleigh

30030

i-Research, Atlanta, Decatur

30060

Psych Atlanta, PC, Marietta

31405

iResearch, Savannah

33014

Meridian International Research, Miami

33125

Global Medical Institutes (GMI), Miami

33133

CCM Clinical Reseach Group, LLC, Miami

60123

Revive Research Institute, Inc., Elgin

75093

AIM Trials, Plano

75231

FutureSearch Trials of Dallas, LP, Dallas

89102

Altea Research, Las Vegas

90660

California Neuropsychopharmacology Clinical Research Institute, Pico Rivera

92103

Artemis Institute for Clinical Research, San Diego

92503

Artemis Institute for Clinical Research, Riverside

92805

Advanced Research Center, Anaheim

94549

Sunwise Clinical Research, LLC, Lafayette

08009

Hassman Research Institute, Marlton

08755

Bio Behavioral Health, Toms River

All Listed Sponsors
lead

Xenon Pharmaceuticals Inc.

INDUSTRY